Stock KURA KURA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kura Oncology, Inc.

Equities

KURA

US50127T1097

Real-time Estimate Cboe BZX
Other stock markets
 11:16:39 2024-06-06 am EDT 		5-day change 1st Jan Change
22.14 USD +1.63% Intraday chart for Kura Oncology, Inc. +6.67% +53.48%
May. 24 Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001 CI
May. 15 Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kura Oncology to Participate in Jefferies Global Healthcare Conference
AQ
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology : Corporate Presentation - May 2024
PU
Kura Oncology: Q1 Earnings Snapshot
AQ
Kura Oncology Reports First Quarter 2024 Financial Results
AQ
Kura Oncology to Report First Quarter 2024 Financial Results
AQ
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology to Participate in Stifel Targeted Oncology Forum
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology: Q4 Earnings Snapshot
AQ
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
AQ
Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KURA Stock
  4. News Kura Oncology, Inc.
  5. Press Releases